Corporate

• About Us
• Careers
• Investors - Investor relations
• Leadership Team
• Scientific Advisors
• Strategic Partners
• Vision & Mission
• What we do
• News
• Resources
• Blog

Products

• Isotype Controls
• Primary Antibodies
• Recombinant Cell Lines
• Isogenic Cell Lines
• FFPE
• Cell Pellets
• Genomic DNA
• Recombinant Proteins
• TMAs

CVMD

Home

Cardiovascular Disease

• NHP Models
• Rodent Models

Diabetes

• NHP Models
• Rodent Models

NAFLD/NASH

• NHP Models
• FATZO

Obesity

• NHP Models
• Rodent Models

Renal Disease

• NHP Models
• Rodent Models

Safety/Toxicology

• Non-GLP Toxicology
• Safety Pharmacology

Inflammation

• Inflammatory Bowel Disease (IBD)
• Rheumatoid Arthritis (RA)

Oncology

Immuno-Oncology

• CAR-T Cell Therapy Models
  • Cell Line Derived Xenografts Targeting CD19
  • PDX
• Humanized Models
  • Hematopoietic Stem Cell (HSC)-PDX
  • HuGEMM
  • HuCELL
  • MiXeno
• Murine Efficacy/PD Models
  • Tumor Homograft Models
  • Syngeneic tumor models
• MuScreen

In Vitro Services

• Cell Based Screening
  • CrownSyn
• Cell Line Panels
• FACS Platform
• Immuno-Oncology
• OmniScreen Cell Based Screening Service
• PDX-Derived Cell Lines

In Vivo Services

• Breast Cancer Preclinical Models
• Cell Line Derived Xenograft Models
• Custom Tumor Model Development
• Immuno-Oncology Models
• MuScreen
• Optical Imaging Platforms for Advanced Preclinical Modeling
• Patient-Derived Xenograft Models (HuPrime/HuKemia)
• Prostate Cancer Preclinical Models
• Radiation Therapy
• Syngeneic Tumor Models

Oncology

Ex Vivo Services

• 3D Assays
• Tumor Microarrays

Oncology Databases

• HuBase
• MuBase
• OncoExpress
• XenoBase

Pharmacology and Bioanalytical Services

• ADME & Physicochem
• Bioanalysis Studies
• FACS Platform
• In Vivo PK/PD
• Structural Biology
• Target Validation

Translational Oncology

• 1+1 Mouse Trial
• Biomarkers of Response (HuMark)
• Mouse Clinical Trials (HuTrial)
• Signatures of Response (HuSignature)